Open AccessPhase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients
Author(s) -
Éric Deutsch,
Christine Haie-Méder,
Mohamed Amine Bayar,
Michele Mondini,
Mélanie Laporte,
R. Mazeron,
Julien Adam,
Andréa Varga,
Gilles Vassal,
Nicolas Magné,
Cyrus Chargari,
Émilie Lanoy,
Patricia Pautier,
Antonin Lévy,
JeanCharles Soria
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.8224
Subject(s) - medicine , cidofovir , cervical cancer , neutropenia , population , adverse effect , gastroenterology , oncology , cancer , urology , surgery , toxicity , immunology , virus , environmental health
This phase I trial aimed to assess the safety and determine the recommended Phase II dose (RP2D) of Cidofovir combined with chemoradiotherapy in patients with stage IB2-IVA cervical cancer.